Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $25.00 price target on the stock. HC Wainwright also issued estimates for Milestone Pharmaceuticals' Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.02) EPS, FY2026 earnings at ($0.89) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.43 EPS and FY2029 earnings at $1.81 EPS.
Milestone Pharmaceuticals Stock Performance
Shares of NASDAQ MIST traded down $0.05 during midday trading on Monday, hitting $1.90. 2,242,755 shares of the company's stock traded hands, compared to its average volume of 451,820. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The stock has a market capitalization of $101.37 million, a price-to-earnings ratio of -2.35 and a beta of 1.83. The firm has a fifty day moving average of $2.02 and a 200 day moving average of $1.81. Milestone Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $2.75.
Institutional Investors Weigh In On Milestone Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of MIST. Jones Financial Companies Lllp lifted its position in Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after purchasing an additional 10,000 shares in the last quarter. National Bank of Canada FI raised its stake in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after buying an additional 11,600 shares during the period. Atria Investments Inc lifted its position in shares of Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company's stock valued at $61,000 after buying an additional 12,430 shares in the last quarter. PVG Asset Management Corp bought a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at approximately $46,000. Finally, Northern Trust Corp increased its holdings in Milestone Pharmaceuticals by 112.6% in the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after acquiring an additional 30,772 shares in the last quarter. 86.18% of the stock is currently owned by hedge funds and other institutional investors.
Milestone Pharmaceuticals Company Profile
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Further Reading
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
